BRIACELL THERAP BCTX
4.32
0.04
0.93%
as of 25 Sep
- Market cap
- $37.2M
- P/E
- 1.9×
Follow BCTX
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.07 | 10.10 | 3.42 | 5.01 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.01 | 3.98 | 1.23 | 2.10 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 1.10 | 0.94 | 1.01 | |
Capex/Depreciation |
(3.85) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.99) | (2.84) | (4.09) | (19.22) | |
Cash per Share |
3.15 | 10.67 | 5.40 | 42.23 | |
Shareholders Equity per Share |
3.23 | 10.78 | 4.96 | 40.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.23 | 10.78 | 4.96 | 40.97 | |
Free Cash Flow |
(7.15) | (7.97) | (7.70) | (8.13) | |
Working Capital |
21.80 | 28.99 | 8.03 | 15.95 | |
Capital Expenditures |
(0.13) | — | — | — | |
Net Current Asset Value |
21.73 | 28.80 | 7.62 | 15.61 | |
| Other line items | |||||
Quick Ratio |
7.07 | 10.10 | 3.42 | 5.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.97) | (2.84) | (4.09) | (19.22) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Average Receivables |
2.46 | 2.21 | 1.80 | 2.43 | |
Average Payables |
2.73 | 3.44 | 3.18 | 5.23 | |
Average Assets |
22.04 | 21.48 | 11.74 | 13.76 | |
Average Common Equity |
17.68 | 16.72 | 6.53 | 7.32 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates